Psychosis in Parkinson’s disease: a clinical biomarker of disease stage and prognosis

Introduction Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor and nonmotor symptoms, the latter contributing significantly to morbidity, mortality, nursing home placement quality of life. Objectives We present literature review about impact psychosis on PD’s prognosis. Methods A performed PUBMED, using next keywords: "Parkinson’s disease”, “psychosis” “prognosis”. focused data from systematic reviews, clinical trials meta-analysis published in English last 10 years. Results Psychosis common feature disease, occurring up 30% PD patients treated chronically with antiparkinsonian drugs. Visual hallucinations are most psychotic symptom observed, delusions being considerably less affecting only 5% patients. Positive symptoms vary across its course: early passage hallucinations, illusions presence occur; later, complete visual initially good insight, then without insight. spectrum predict decline cognitive function at 2 years, especially hallucinations. There an association between subsequent emergence dementia. Conclusions Current evidence highlights role as biomarker stage, distribution future progression. Early recognition treatment improves disease’s outcomes. Disclosure Interest None Declared